BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 26024285)

  • 1. ESBL-producing enterobacteriaceae-related urinary tract infections in kidney transplant recipients: incidence and risk factors for recurrence.
    Pilmis B; Scemla A; Join-Lambert O; Mamzer MF; Lortholary O; Legendre C; Zahar JR
    Infect Dis (Lond); 2015; 47(10):714-8. PubMed ID: 26024285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary tract infections caused by ESBL-producing Enterobacteriaceae in renal transplant recipients: A systematic review and meta-analysis.
    Alevizakos M; Nasioudis D; Mylonakis E
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28803446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae-Related Urinary Tract Infection in Kidney Transplant Recipients: Risk Factors, Treatment, and Long-Term Outcome.
    Brakemeier S; Taxeidi SI; Zukunft B; Schmidt D; Gaedeke J; Dürr M; Hansen S; Budde K
    Transplant Proc; 2017 Oct; 49(8):1757-1765. PubMed ID: 28923621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary Tract Infections in Kidney Transplant Patients Due to Escherichia coli and Klebsiella pneumoniae-Producing Extended-Spectrum β-Lactamases: Risk Factors and Molecular Epidemiology.
    Espinar MJ; Miranda IM; Costa-de-Oliveira S; Rocha R; Rodrigues AG; Pina-Vaz C
    PLoS One; 2015; 10(8):e0134737. PubMed ID: 26237422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of ESBL-producing Enterobacteriaceae in paediatric urinary tract infections: A systematic review and meta-analysis.
    Flokas ME; Detsis M; Alevizakos M; Mylonakis E
    J Infect; 2016 Dec; 73(6):547-557. PubMed ID: 27475789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary tract infection caused by extended-spectrum beta-lactamase-producing bacteria in kidney transplant patients.
    Pinheiro HS; Mituiassu AM; Carminatti M; Braga AM; Bastos MG
    Transplant Proc; 2010 Mar; 42(2):486-7. PubMed ID: 20304172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergency Department Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Many Patients Have No Identifiable Risk Factor and Discordant Empiric Therapy Is Common.
    Frazee BW; Trivedi T; Montgomery M; Petrovic DF; Yamaji R; Riley L
    Ann Emerg Med; 2018 Oct; 72(4):449-456. PubMed ID: 29980462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial resistance in community-acquired urinary tract infections in Paris in 2015.
    Chervet D; Lortholary O; Zahar JR; Dufougeray A; Pilmis B; Partouche H
    Med Mal Infect; 2018 May; 48(3):188-192. PubMed ID: 29054298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of infection caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: development of a clinical decision-making nomogram.
    García-Tello A; Gimbernat H; Redondo C; Meilán E; Arana DM; Cacho J; Dorado JF; Angulo JC
    Scand J Urol; 2018 Feb; 52(1):70-75. PubMed ID: 28893132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-spectrum β-lactamase-producing Enterobacteriaceae, national study of antimicrobial treatment for pediatric urinary tract infection.
    Lagree M; Bontemps S; Dessein R; Angoulvant F; Madhi F; Martinot A; Cohen R; Dubos F;
    Med Mal Infect; 2018 May; 48(3):193-201. PubMed ID: 29449049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ongoing increasing temporal and geographical trends of the incidence of extended-spectrum beta-lactamase-producing Enterobacteriaceae infections in France, 2009 to 2013.
    Arnaud I; Maugat S; Jarlier V; Astagneau P;
    Euro Surveill; 2015; 20(36):. PubMed ID: 26536042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria.
    Briongos-Figuero LS; Gómez-Traveso T; Bachiller-Luque P; Domínguez-Gil González M; Gómez-Nieto A; Palacios-Martín T; González-Sagrado M; Dueñas-Laita A; Pérez-Castrillón JL
    Int J Clin Pract; 2012 Sep; 66(9):891-6. PubMed ID: 22897466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for community-onset urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Tüzün T; Sayın Kutlu S; Kutlu M; Kaleli İ
    Turk J Med Sci; 2019 Aug; 49(4):1206-1211. PubMed ID: 31385490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.
    Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL
    Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of extended-spectrum cephalosporin-resistance in recurrent community-onset Enterobacteriaceae urinary tract infections: a retrospective cohort study.
    Anesi JA; Lautenbach E; Nachamkin I; Garrigan C; Bilker WB; Omorogbe J; Dankwa L; Wheeler M; Tolomeo P; Han JH;
    BMC Infect Dis; 2019 Feb; 19(1):163. PubMed ID: 30764770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Asakura T; Ikeda M; Nakamura A; Kodera S
    Int J Infect Dis; 2014 Dec; 29():91-5. PubMed ID: 25461239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence of urinary tract infections and development of urinary-specific antibiogram for kidney transplant recipients.
    Korayem GB; Zangeneh TT; Matthias KR
    J Glob Antimicrob Resist; 2018 Mar; 12():119-123. PubMed ID: 28859935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
    Raja NS
    J Infect Public Health; 2019; 12(6):843-846. PubMed ID: 31176606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International travel is a risk factor for extended-spectrum β-lactamase-producing Enterobacteriaceae acquisition in children: A case-case-control study in an urban U.S. hospital.
    Strysko JP; Mony V; Cleveland J; Siddiqui H; Homel P; Gagliardo C
    Travel Med Infect Dis; 2016; 14(6):568-571. PubMed ID: 27890813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing bacteria in children.
    Dalgic N; Sancar M; Bayraktar B; Dincer E; Pelit S
    Scand J Infect Dis; 2011 May; 43(5):339-43. PubMed ID: 21271945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.